Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (8531)	1/27/2002 11:42:29 PM
From: DaveAu	Read Replies (2) \| Respond to of 14101

Jim, These terms phase 1, 2, and 3 are a little misleading. The WF10 "phase 2" trials involved a very small number of patients. There is absolutely no possibility of any drug being approved by the FDA on the basis of such small trials. One example I'm familiar with is AXO. They just announced mixed results of their phase "2b" trial in cancer. Having been granted FDA fast track, they intended to file for FDA approval after this trial but note that the 2b trial enrolled 350 patients (far more than the WF10 phase 3) and they also had several other phase 2 trials which put them over 500 patients that actually received the drug as opposed to the placebo. While I'm thinking of AXO: they had a delay in announcing the results and it turned out that it was due to how crummy their results were. They needed time to try to put a positive spin on it. Is DMX/Oxo now doing the same thing with WF10 ? It shouldn't take this long. Dave